Neomycin And Polymyxin B Sulfates And Bacitracin Zinc label

Neomycin And Polymyxin B Sulfates And Bacitracin Zinc

Neomycin And Polymyxin B Sulfates And Bacitracin Zinc Recall

Get an alert when a recall is issued.

Side Effects & Adverse Reactions

NOT FOR INJECTION INTO THE EYE.

Neomycin and polymyxin B sulfates and bacitracin zinc ophthalmic ointment should never be directly introduced into the anterior chamber of the eye. Ophthalmic ointments may retard corneal wound healing.

Topical antibiotics, particularly neomycin sulfate, may cause cutaneous sensitization. A precise incidence of hypersensitivity reactions (primarily skin rash) due to topical antibiotics is not known. The manifestations of sensitization to topical antibiotics are usually itching, reddening, and edema of the conjunctiva and eyelid. A sensitization reaction may manifest simply as a failure to heal. During long-term use of topical antibiotic products, periodic examination for such signs is advisable, and the patient should be told to discontinue the product if they are observed. Symptoms usually subside quickly on withdrawing the medication. Application of products containing these ingredients should be avoided for the patient thereafter (see PRECAUTIONS: General).

FDA Safety Alerts

There are currently no FDA safety alerts available for this drug.

Manufacturer Warnings

There is currently no manufacturer warning information available for this drug.

FDA Labeling Changes

There are currently no FDA labeling changes available for this drug.

Uses

Neomycin and polymyxin B sulfates and bacitracin zinc ophthalmic ointment is indicated for the topical treatment of superficial infections of the external eye and its adnexa caused by susceptible bacteria. Such infections encompass conjunctivitis, keratitis and keratoconjunctivitis, blepharitis and blepharoconjunctivitis.

History

There is currently no drug history available for this drug.

Other Information

Neomycin and Polymyxin B Sulfates and Bacitracin Zinc Ophthalmic Ointment USP is a sterile antimicrobial ointment for ophthalmic use.

Each Gram Contains:

ACTIVES: Neomycin Sulfate (equivalent to 3.5 mg neomycin base), Polymyxin B Sulfate equivalent to 10,000 polymyxin B units, and Bacitracin Zinc equivalent to 400 bacitracin units; INACTIVES: White Petrolatum, Mineral Oil.

Neomycin sulfate is the sulfate salt of neomycin B and C, which are produced by the growth of Streptomyces fradiae Waksman (Fam. Streptomycetaceae). It has a potency equivalent of not less than 600 micrograms of neomycin standard per milligram, calculated on an anhydrous basis. The structural formulae are:

Neomycin Sulfate Chemical Structure

Polymyxin B sulfate is the sulfate salt of polymyxin B1 and B2 which are produced by the growth of Bacillus polymyxa (Prazmowski) Migula (Fam. Bacillaceae). It has a potency of not less than 6,000 polymyxin B units per milligram, calculated on an anhydrous basis.

The structural formulae are:

Polymyxin B Sulfate Chemical Structure

Bacitracin zinc is the zinc salt of bacitracin, a mixture of related cyclic polypeptides (mainly bacitracin A) produced by the growth of an organism of the licheniformis group of Bacillus subtilis var Tracy. It has a potency of not less than 40 bacitracin units per milligram.

The structural formula for bacitracin A is:

Bacitracin Zinc Chemical Structure

Neomycin And Polymyxin B Sulfates And Bacitracin Zinc Manufacturers

  • Neomycin And Polymyxin B Sulfates And Bacitracin Zinc | Rebel Distributors Corp
    No Recall

    Neomycin And Polymyxin B Sulfates And Bacitracin Zinc | Rebel Distributors Corp

    Neomycin And Polymyxin B Sulfates And Bacitracin Zinc | Rebel Distributors Corp

    Apply the ointment every 3 or 4 hours for 7 to 10 days, depending on the severity of the infection.

  • Lake Erie Medical Dba Quality Care Products Llc
    Neomycin And Polymyxin B Sulfates And Bacitracin Zinc | Lake Erie Medical Dba Quality Care Products Llc
    No Recall

    Neomycin And Polymyxin B Sulfates And Bacitracin Zinc | Lake Erie Medical Dba Quality Care Products Llc

    Neomycin And Polymyxin B Sulfates And Bacitracin Zinc | Lake Erie Medical Dba Quality Care Products Llc

    Apply the ointment every 3 or 4 hours for 7 to 10 days, depending on the severity of the infection.

  • Rxv
    Neomycin And Polymyxin B Sulfates And Bacitracin Zinc | Rxv
    No Recall

    Neomycin And Polymyxin B Sulfates And Bacitracin Zinc | Rxv

    Neomycin And Polymyxin B Sulfates And Bacitracin Zinc | Rxv

    Apply the ointment every 3 or 4 hours for 7 to 10 days, depending on the severity of the infection.

  • Neomycin And Polymyxin B Sulfates And Bacitracin Zinc | Kvk-tech, Inc.
    No Recall

    Neomycin And Polymyxin B Sulfates And Bacitracin Zinc | Kvk-tech, Inc.

    Neomycin And Polymyxin B Sulfates And Bacitracin Zinc | Kvk-tech, Inc.

    The initial dose of betaxolol tablets, USP in hypertension is ordinarily 10 mg once daily either alone or added to diuretic therapy. The full antihypertensive effect is usually seen within 7 to 14 days. If the desired response is not achieved the dose can be doubled after 7 to 14 days. Increasing the dose beyond 20 mg has not been shown to produce a statistically significant additional antihypertensive effect; but the 40-mg dose has been studied and is well tolerated. An increased effect (reduction) on heart rate should be anticipated with increasing dosage. If monotherapy with betaxolol tablets, USP does not produce the desired response, the addition of a diuretic agent or other antihypertensive should be considered (see PRECAUTIONS, Drug Interactions).

    Dosage Adjustments For Specific Patients:

    Patients with renal failure:

    In patients with renal impairment, clearance of betaxolol declines with decreasing renal function.

    In patients with severe renal impairment and those undergoing dialysis, the initial dose of betaxolol tablets, USP is 5 mg once daily. If the desired response is not achieved, dosage may be increased by 5 mg/day increments every 2 weeks to a maximum dose of 20 mg/day.

    Patients with hepatic disease:

    Patients with hepatic disease do not have significantly altered clearance. Dosage adjustments are not routinely needed.

    Elderly patients:

    Consideration should be given to reduction in the starting dose to 5 mg in elderly patients. These patients are especially prone to beta-blocker-induced bradycardia, which appears to be dose related and sometimes responds to reductions in dose.

    Cessation of therapy:

    If withdrawal of betaxolol tablets, USP therapy is planned, it should be achieved gradually over a period of about 2 weeks. Patients should be carefully observed and advised to limit physical activity to a minimum.